Effects of different doses of Atorvastatin combined with Two dibutyryl cyclic adenosine phosphate calcium glycosides on cardiac function and NT-proBNP in patients with coronary heart disease complicated with chronic heart failure
张文,肖勇,高妍,贾兴泽,林荣,曹梅娜,夏豪
DOI: https://doi.org/10.3969/j.issn.1672-5301.2018.01.017
2018-01-01
Abstract:Objective To investigate the effect of different doses of Atorvastatin combined with Two dibutyryl cyclic adenosine phosphate calcium on cardiac function and NT-proBNP in patients with coronary heart disease complicated with chronic heart failure.Methods From June 2015 to December 2016,116 patients with coronary heart disease and chronic heart failure admitted in Jizhong energy Xingtai mining Refco Group Ltd General Hospital were enrolled and were randomly divided into control group,low dose group,middle dose group and high dose group according to the treatment,each group has 29 cases.The control group received routine treatment after admission,while the observation group was given Atorvastatin combined with Two dibutyryl cyclic adenosine phosphate calcium on the basis of the treatment in the control group.The dose of Atorvastatin used in different dose groups was different.The therapeutic effects were compared among four groups.Results NT-proBNP,C-reactive protein,left ventricular ejection fraction and left ventricular end diastolic diameter before treatment had no significant difference among four groups(P＞0.05);after treatment,in control group the levels of NT-proBNP,C-reactive protein,left ventricular ejection fraction,left ventricular end diastolic diameter changed from (955.34±113.58)pg/ml,(23.46±4.53)mg/L,(38.41±2.11)％,(57.53±3.57)mm to(851.08±98.83)pg/ml,(21.37±3.25)mg/L,(39.79±3.01)％ and (55.80±2.89)mm respectively;in low dose group,they were from(955.87±103.71)pg/ml,(24.18±4.48)mg/L,(39.21±2.52)％,(57.48±3.64)mm to(848.12±102.83)pg/ml,(21.11±3.16)mg/L,(41.00±3.22)％,(54.91 ±3.55)mm respectively;in middle dose group changed from(956.28±105.86)pg/ml,(23.78±4.57)mg/L,(38.52±2.34)％,(56.52±3.28)mm to (921.23±93.64)pg/ml,(20.84±3.22)mg/L,(41.81 ±3.57)％,(53.99±4.25)mm,four indexes in high dose group were respectively from (956.49±118.12)pg/ml,(24.55±4.62)mg/L,(38.74±2.21)％,(56.13±3.91)mm to (794.62±112.57)pg/ml,(19.12±2.88)mg/L,(42.54±4.36)％,(48.38±3.81)mm,the difference between the four groups after treatment in four patients indexes before and after treatment were statistically significant (P＜0.05).After treatment,the NT-proBNP,C-reactive protein and left ventricular end diastolic diameter were lower than that before treatment,and the left ventricular ejection fraction was higher than that before treatment.The difference of treatment effect between the four groups was statistically significant (x2=35.119,P＜0.05),and the difference in the effective rate of treatment was also statistically significant (x2=8.627,P＜0.05).Bonferonni test 22 comparison x2 test results showed that the difference between the high-dose group and the other three groups was statistically significant (P＜0.05),and the difference between the control group,the low-dose group and the middle dose group was not statistically significant (P＞0.05).Conclusion The use of high doses of Atorvastatin combined with two dibutyryl cyclic adenosine phosphate calcium on coronary heart disease patients with chronic heart failure treatment,can improve heart function,improve NT-proBNP and C-reactive protein index,improve the therapeutic effect,worthy of promotion in a wider range of clinical.